{
    "organizations": [],
    "uuid": "53cd9e08b80f9b0a65f4b230c9a8bbe08887dbc2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-spectrum-pharmaceuticals-announces/brief-spectrum-pharmaceuticals-announces-rolontis-met-the-primary-endpoint-in-the-phase-3-advance-study-idUSFWN1PV0SZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 17 PM / in 7 minutes BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study Reuters Staff \nFeb 5 (Reuters) - Spectrum Pharmaceuticals Inc: \n* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTISâ„¢ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY \n* SPECTRUM PHARMACEUTICALS INC - ADVANCE STUDY MET PRIMARY EFFICACY ENDPOINT \n* SPECTRUM PHARMACEUTICALS - PLANS TO FILE BLA FOR RECOVER PHASE 3 STUDY IN Q4 THIS YEAR Source text for Eikon: Further company coverage:",
    "published": "2018-02-05T14:15:00.000+02:00",
    "crawled": "2018-02-05T14:32:38.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "pharmaceutical",
        "announces",
        "rolontis",
        "met",
        "primary",
        "endpoint",
        "phase",
        "advance",
        "study",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "spectrum",
        "pharmaceutical",
        "inc",
        "spectrum",
        "pharmaceutical",
        "announces",
        "eflapegrastim",
        "met",
        "primary",
        "endpoint",
        "phase",
        "advance",
        "study",
        "spectrum",
        "pharmaceutical",
        "inc",
        "advance",
        "study",
        "met",
        "primary",
        "efficacy",
        "endpoint",
        "spectrum",
        "pharmaceutical",
        "plan",
        "file",
        "bla",
        "recover",
        "phase",
        "study",
        "q4",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}